Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Original Maker Recalls Nizatidine over Carcinogen Risks
December 4, 2019
- Vyvanse Now Available in Japan 6 Months after Listing
December 4, 2019
- Astellas, Seattle Genetics Join Hands with US Merck for ADC/Keytruda Combo
December 4, 2019
- Takeda Launches Zafatek 25 mg for Patients with Renal Dysfunction
December 4, 2019
- Shire Rolls Out Kit Version of Advate IV in Japan
December 4, 2019
- Idelvion’s 3500 IU Vials Available in Japan: CSL Behring
December 4, 2019
- Lenvima’s Add’l Thyroid Cancer Use Accepted for Chinese Regulatory Review
December 3, 2019
- Zykadia’s Film-Coated Tablets Now Available
December 3, 2019
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Crysvita’s Japan Launch Set for Dec. 6: Kyowa Kirin
December 3, 2019
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
- Shionogi Introduces AI Chatbot for Xofluza Inquiries from Medical Professionals
December 3, 2019
- Satralizumab Reduces Risk of NMOSD Relapses: Chugai
December 2, 2019
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
- Boehringer Innovation Chief Touts R&D Efforts on Undruggable Cancer Targets
December 2, 2019
- Santen Starts Voluntary Recall of Pivalephrine
December 2, 2019
- Takeda Submits Niraparib for Ovarian Cancer in Japan
December 2, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…